Interestingly, patients with high UCHL5 expression have better prognosis in later stages of both pancreatic and rectal cancer [3,4], whereas a similar survival benefit was linked to lower stages (stages I-II) of gastric cancer. Here, UCHL5 is linked to gastric cancer.